THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS
https://doi.org/10.14412/1995-4484-2020-233-237
Abstract
At present, there is more and more evidence in rheumatology on the factors influencing the efficacy of biological agents (BAs), and there is no generally accepted algorithm for managing patients resistant to standard therapy. The paper describes three patients with ankylosing spondylitis (AS) who were followed up at the V.A. Nasonova Research Institute of Rheumatology in 2011–2019. All the patients showed a severe course of AS of high clinical and laboratory activities, extra-articular manifestations, and inefficacy of three or more BAs. All the patients share the following symptoms: male gender, early onset of disease, high clinical and laboratory activities, and extra-articular manifestations, such as uveitis and psoriasis.
About the Authors
D. G. Rumyantseva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
M. V. Podryadnova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
O. A. Rumyantseva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
M. M. Urumova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Sh. Erdes
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(6):657-60. doi: 10.14412/1995-4484-2015-657-660 (In Russ.)
2. Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91. doi: 10.1136/annrheumdis-2016-210770
3. Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815-22. doi: 10.1136/annrheumdis-2012-201766
4. Rudwaleit M, Schwarzlose S, Hilgert ES, et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67:1276-81. doi: 10.1136/ard.2007.073098
5. Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheum. 2015;67:2702-12. doi: 10.1002/art.39257
6. Vastesaeger N, Cruyssen BV, Mulero J, et al. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. Reumatol Clin. 2014;10:204-9. doi: 10.1016/j.reuma.2013.12.006
7. Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70:973-81. doi: 10.1136/ard.2010.147744
8. Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009;36:801-8. doi: 10.3899/jrheum.081048
9. Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72(7):1149-55. doi: 10.1136/annrheumdis-2012-201933
10. Ciurea A, Exer P, Weber U, et al. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther. 2016;18(1):71. doi: 10.1186/s13075-016-0969-2
11. Polo y La Borda J, Campos J, Sanz J, et al. Predictive clinicalgenetic model of long-term non-response to tumor necrosis factor-alpha inhibitor therapy in spondyloarthritis. Int J Rheum Dis. 2019;22(8):1529-37. doi: 10.1111/1756-185X.13607
12. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(3):711-5. doi: 10.1002/art.21671
13. Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature. 1964;203:1352-4. doi: 10.1038/2031352a0
14. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009 May;21(3):211-5. doi: 10.1097/BOR.0b013e328329ed8b
15. De Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(4):531-5. doi: 10.1136/ard.2008.089979
16. Garces S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2014;73(6):1138-43. doi: 10.1136/annrheumdis-2013-203296
17. Reid V, Castelino M, Parker B, et al. Harmonised Biologics Pathway for Ankylosing Spondylitis (including non-radiographic axial spondyloarthritis – AS) and Psoriatic Arthritis PsA. 2018. Available at: http://gmmmg.nhs.uk/docs/guidance/GMMMGAS-PsA-pathway-v4-2a.pdf
18. Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011 Jun 27;13(3):R105. doi: 10.1186/ar3386
19. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheum. 2019;71(10):1599-613. doi: 10.1002/art.41042
Review
For citations:
Rumyantseva D.G., Podryadnova M.V., Rumyantseva O.A., Urumova M.M., Erdes Sh. THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS. Rheumatology Science and Practice. 2020;58(2):232-237. (In Russ.) https://doi.org/10.14412/1995-4484-2020-233-237
Views:
630
Email this article 